Related Experiment Videos
Allochimeric therapy induces unique regulatory T cells that mitigate chronic rejection
N V Semiletova1, X D Shen, S J Slomowitz
1Dumont-UCLA Transplant Center, Los Angeles, California, USA.
Transplantation Proceedings
|April 6, 2005
Summary
Allochimeric therapy, using engineered MHC antigens, induces donor-specific tolerance to cardiac allografts by generating regulatory T cells (T-regs). This process actively prevents chronic rejection and alloantibody responses, offering a path beyond immunosuppression.
Area of Science:
- Transplantation immunology
- Immunogenetics
- Regulatory T cell biology
Background:
- Inducing allograft tolerance without broad immunosuppression is a key goal in transplantation.
- Allochimeric therapy with engineered MHC antigens has shown promise in inducing donor-specific tolerance.
- Mechanisms underlying transplantation tolerance, particularly the role of regulatory T cells (T-regs) and chronic rejection (CR), require further elucidation.
Purpose of the Study:
- To investigate the mechanisms of chronic rejection (CR) development in a cardiac transplant tolerance model.
- To examine the role of regulatory T cells (T-regs) generated through adoptive transfer and allochimeric therapy.
- To understand how allochimeric therapy influences regulatory lymphocytes and mitigates CR.
Main Methods:
- Generation of T-regs in vitro via mixed lymphocyte reaction (MLR) coculture.
- Adoptive transfer of T-regs from primary to secondary and tertiary recipients to assess regulatory function.
- Histological evaluation to assess chronic rejection in T-reg-treated and control groups.
- Comparison of T-regs generated with allochimeric therapy versus those from cyclosporine-treated recipients.
Main Results:
- Adoptive transfer of T-regs from tolerant hosts, but not naive rats, prolonged graft survival.
- Histological analysis revealed an absence of chronic rejection in T-reg-transfected groups.
- T-regs generated with allochimeric therapy effectively mitigated CR, unlike those from cyclosporine treatment.
- Allochimeric therapy induced unique regulatory lymphocytes that suppressed alloantibody responses.
Conclusions:
- Allochimeric therapy promotes the generation of potent regulatory lymphocytes crucial for establishing transplantation tolerance.
- These regulatory cells actively prevent chronic rejection by modulating inflammatory responses and down-regulating alloantibody production.
- This approach offers a novel strategy for inducing specific tolerance to allografts, potentially reducing the reliance on nonspecific immunosuppression.